TARGETING THE SOURCE OF INFLAMMATION
Modifying the Course of Autoimmune Disease
At Celexor Bio, we aim to solve the challenges of severe autoimmune disorders by starting at the source – stopping the inflammatory cascade and modifying the course of disease.
About Us
Starting at the Source to Change the Future in Autoimmune and Inflammatory Disorders
Celexor Bio is dedicated to the development of robust therapeutic solutions that transform the treatment of severe, underserved autoimmune and inflammatory disorders.
We’re focused on stopping the inflammatory process at its source through targeted therapies that selectively deplete plasmacytoid dendritic cells (pDCs). Secreting high levels of pro-inflammatory cytokines, pDCs are the primary driver of disease pathology across multiple disorders.
In the treatment of pDC-driven autoimmune diseases, the therapeutic options that comprise the current standard of care act downstream to limit inflammation and immune response to minimize symptoms. Our team is pursuing a new therapeutic approach: one that aims to directly remove the upstream source of inflammation. By intervening at the start of the inflammatory cascade and depleting pDCs, our approach is designed to uniquely impact and improve patient outcomes – going beyond symptomatic treatment and modifying the course of disease.
Our Focus
Targeting the Pathogenic Roles of pDCs in Autoimmune Disease
At Celexor Bio, we’re focused on pDCs as a promising therapeutic target in the treatment of autoimmune and inflammatory disorders. Our drug development strategy is aimed at the depletion of pathological pDCs – removing a known driver of inflammation with the potential to halt the inflammatory process at its source.
Plasmacytoid dendritic cells (pDCs) play an important role in immune system functioning and defense against viral infections. Excessive activation of pDCs, however, leads to the overproduction of type I interferons and other pro-inflammatory cytokines. This pathological activation of pDCs is a trigger of the inflammatory cascade that has a causal role in autoimmune and inflammatory disorders.
pDCs are the central driver of pathology in several severe and underserved autoimmune diseases
CLXR-901 offers disease modifying potential by directly removing the upstream source of inflammation
Biomarkers show a direct link between pDC activation and pathology
Our Approach
Modifying Disease at the Source
Celexor Bio aims to translate our focus on the depletion of pDCs into a therapeutic solution with the potential to modify the course of disease by directly removing the central source of inflammation – at the start of the inflammatory cascade.
Advancing a New Treatment Paradigm
The promise of our paradigm-shifting approach is embodied in our lead product candidate, CLXR-901, a monoclonal antibody (mAb) targeting immunoglobulin-like transcript 7 (ILT7), a highly specific cell surface marker found on plasmacytoid dendritic cells. CLXR-901 rapidly and potently depletes these pathological cells, underscoring its potential as a safe and effective new treatment option for severe autoimmune and inflammatory disorders.
Investigational New Drug (IND)-enabling studies of CLXR-901 are currently ongoing with clinical studies anticipated to begin in 2025.
Our Team
Experienced Leadership Advancing the Charge for Celexor Bio.
LEADERSHIP
Connect with us.
For general, corporate or business development inquiries, please contact us.
1111 Broadway #1300, Oakland, CA 94607
Tel: +1 (510) 227-2102
Email: info@celexorbio.com